Abstract
Lipid nanoparticles (LNPs) have rendered mRNA therapeutics clinically viable, yet their design remains impeded by tightly intertwined chemical, physical, biological, and manufacturing variables. This review argues that artificial intelligence (AI)-assisted LNP design should be approached as multiscale therapeutic-system engineering rather than reduced to isolated predictive tasks. We propose that AI models must holistically integrate ionizable lipid chemistry, supramolecular assembly, protein corona remodeling, endosomal escape, organ- and cell-specific tropism, cargo attributes, safety profiles, and process robustness into a cohesive framework. Current studies demonstrate that machine learning can prioritize ionizable lipids, predict formulation properties, guide tissue-selective delivery, and expedite the design–build–test–learn cycle. However, many models remain constrained by insufficient sample sizes, poor in vitro/in vivo translation, reliance on random-split validation, and narrow potency-centric endpoints. We propose and apply a claim-specific evidence hierarchy for AI-LNP studies and propose standardized multimodal datasets, mechanism-informed descriptors, scaffold-level holdout tests, and manufacturability-aware objective functions. We conclude that digital models of LNP delivery must be treated as emerging hypotheses until anchored by prospective and clinically relevant evidence.